natgillin/translations-raw huggingface dataset:
In one embodiment the IOP of the affected eye is reduced by at least 10% for more than 3 hours, e.g., at least 10-20% for more than 3 hours, e.g., by 20% or more for more than 3 hours. In one embodiment the IOP of the affected eye is reduced by at least 10% for at least 6 hours. 
Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu primjena tvari snižava IOP zahvaćenog oka za najmanje 10% kroz više od 3 sata, ili za najmanje 10-20% kroz više od 3 sata, ili za 20% ili više kroz više od 3 sata ili za najmanje 10% kroz najmanje 6 sati.
represents an indanyl or tetralinyl group substituted or not by one or more groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups; 
R2 predstavlja indanil ili tetralinil skupinu supstituiranu ili ne s jednim ili više skupina odabranih između atoma halogena, alkil skupina, hidroksi, alkoksi skupina, amino, mono- ili di-alkilamino skupina, karboksi skupina, alkiloksikarbonil skupina, mono- ili di-alkilaminokarbonil skupina, karboksamida, cijano, alkilsulfonil 1 trifluorometil skupina;
A kit comprising (a) 2-chloro-2'-deoxyadenosine or pharmaceutically acceptable salts thereof, (b) an anti-alpha-4 integrin antibody which blocks the adhesion of monocytes and leukocytes to endothelial cells and instructions for using said agents to treat multiple sclerosis. 
Kit, naznačen time, da sadrži (a) 2-kloro-2'-deoksiadenozin ili njegove farmaceutski prihvatljive soli, (b) anti-alfa4 integrin antitijelo koje blokira adheziju monocita i leukocita na endotelne stanice, te upute za uporabu navedenih sredstava za liječenje multiple skleroze.
Aliquots of the vehicle control, low and high dosing solutions were collected following treatment of the CHO cells and subsequently analyzed to determine the concentration of the compound of interest. 
Alikvote kontrole sa nosačem, otopina niske i visoke doze su sakupljene poslije tretmana CHO stanica 1 zatim analizirane da se odredi koncentracija spoja od značaja.
at least one hydrating/wetting agent in a quantity between 0% and 20% by weight of the formulation, 
- najmanje jedno sredstvo za hidrataciju odnosno vlaženje u količini između 0 % i 20 %, težinski, formulacije,
The air inversion and steam cure apparatus of claim 2, wherein the gap is adjusted by a plurality of opposed displaceable fingers (133) positioned on both edges to urge the compressible material (46) over the slot opening and against a liner passing through the slot opening. 
Uređaj za sanaciju zračnom inverzijom i parom prema patentnom zahtjevu 2, naznačen time da se raspor prilagođava pomoću mnoštva nasuprotno smještenih pomičnih prstiju (133) smještenih na oba ruba da tjeraju komprosibilni materijal (46) preko otvora za umetanje ina materijal za sanaciju koji prolazi kroz otvor za umetanje.
The use of a compound according to embodiment 17 for the preparation of a medicament for the treatment of Parkinson's disease or Huntington's disease in a mammal. 
Tvar u skladu s patentnim zahtjevom 4 za uporabu u liječenju Parkinsonove bolesti ili Huntingtonove bolesti u sisavaca.
On the other hand, the first and second plunger elements 32, 42 may be movable within the box-like body 10 . 
Spojnica za zatvaranje vrata prema zahtjevu 1, gdje su prvi i drugi klipni elementi (32, 42) uzajamno nasuprotni u odnosu na klin (20).
In a twenty fourth reference example, the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof, wherein: 
20 5. = Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom:
(A2a) a phenyl-substituted lower alkenyl group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group, or 
(A2a) fenil-supstituiranu skupinu niži alkenil s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (supstituentima) na fenilnoj skupini, ili
The method of claim 1, wherein the conversion of ethylene oxide to beta propiolactone is a gas phase reaction, or: wherein the metal carbonyl compound has a formula [QM y (CO) w] x, where: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je prevođenje etilen-oksida u fB-propiolakton reakcija u plinovitoj fazi, ili: gdje metalni karbonilni spoj ima formulu [QM,(CO),]", gdje:
The pram or stroller according to claim 3, wherein the pressure sensor is of mechanical or electrical type and directly connected to the central processing unit. 
Dječja kolica ili kišobran kolica prema patentnom zahtjevu 3, naznačena time, što je senzor pritiska mehaničke ili električne vrste 1 direktno je povezan sa centralnom procesorskom jedinicom.
Advantageously, the modified FIX polypeptide has at least 90% homology (or, advantageously, identity) with a peptide sequence chosen from the group consisting of: SEQ ID NO: 1 and SEQ ID NO: 2. 
Polipeptid za uporabu, sukladno zahtjevu 1, naznačen time, da navedeni peptid ima najmanje 90% identičnosti sa SEQ ID NO: Lili SEQ ID NO: 2.
The compound of formula I will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.2:1 to about 10:1. 
Spoj formule I će se koristiti u odnosu masa prema tiazolidinedionu u količini unutar opsega od oko 0.01:1 do oko 100:1, poželjno od oko 0.2:1 do oko 10:1.
The process according to claim 6, wherein the transition metal compound is a palladium compound. 
Postupak prema zahtjevu 7, u kome je paladijev spoj, paladij (11) spoj.
In a certain embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 5; a heavy chain variable region CDR2 of SEQ ID NO: 12; a heavy chain variable region CDR3 of SEQ ID NO: 19; a light chain variable region CDR1 of SEQ ID NO: 26; a light chain variable region CDR2 of SEQ ID NO: 33; and a light chain variable region CDR3 of SEQ ID NO: 40. 
(d) CDRI varijabilno područje jakog lanca od SEQ ID NO:5; CDR2 varijabilno područje jakog lanca od SEQ ID NO:12; CDR3 varijabilno područje jakog lanca od SEQ ID NO:19; CDRI varijabilno područje slabog lanca od SEQ ID NO:26; CDR2 varijabilno područje slabog lanca od SEQ ID NO:33; i CDR3 varijabilno područje slabog lanca od SEQ ID NO:40; ili
converting at least one hydroxyl group of the oligosaccharide into a blocking group, as described above. 
(c) pretvaranje najmanje jedne hidroksilne skupine u oligosaharidu u blokirajuću skupinu, u skladu s patentnim zahtjevom 11; ili
A pharmaceutical composition comprising a compound according to claim 1, and at least one of a pharmaceutically acceptable: carrier, excipient or diluent. 
Farmaceutski pripravak, naznačen time što sadrži spoj ili pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 15, i najmanje jedno od farmaceutski prihvatljive: podloge, pomoćne tvari ili razrjeđivača.
The product according to claim 1, wherein the toilet paper comprises the mixture of bacterial strains on more than one surface. 
Produkt prema patentnim zahtjevima 1-6, naznačen time da je toaletni papir koji na površini nosi najmanje jednu bakterijsku vrstu.
The method of claim 1, wherein the amount of the acylating agent ranges from about 1 to about 15, from about 1 to about 10, or from about 2 to about 7 molar equivalent per molar equivalent of the compound of formula (II). 
Postupak prema zahtjevu 1, naznačen time da je količina prve baze u rasponu od oko 1 do oko 10, od oko 2 do oko 7 ili od oko 3 do oko 6 molarnih ekvivalenata po molarnom ekvivalentu agensa za acililaranje. .
alternatively, R4 and R5 are taken together with the atom to which they are bound to form a ring structure selected from the group consisting of 2-(2,5-dihydro-furanyl) and 2-tetrahydrofuranyl; or a pharmaceutically acceptable salt thereof. 
Alternativno, R* i R* su uzeti zajedno s atomom na koji su vezani da formiraju 2- [1,3] dioksolanil; ili njihovu farmaceutski prihvatljivu sol. Spoj kao u zahtjevu 1, naznačen time da
The liquid formulation according to claim 1, wherein said salt is the DL-lactic acid addition salt. 
Tekuća formulacija u skladu s patentnim zahtjevom 1, pri čemu je navedena sol dodatna sol DL-mliječne kiseline.
a concentrator configured to communicate with said plurality of remote meters in order to collect consumption data, to perform tasks related to administration of associated remote meters, to transmit a first request for status data to one of the plurality of remote meters, and to transmit a second subsequent request indicating an amount of utility consumption related data to said one of the plurality of remote meters; 
- sabirnika (C) prema patentnom zahtjevu 19 koji je povezan s navedenim velikim brojem daljinskih brojača (RM) kako bi prikupio podatke o potrošnji i proveo zadatke vezano uz upravljanje s njim povezanim daljinskim brojačima; pri čemu su navedeni daljinski brojači (RM) sustava prilagođeni za provođenje operacija prijenosa određeno količine (L) navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju (MV1, MV2...
A method of generating a protein scaffold binding to a specific target with a predefined binding affinity, comprising contacting the library of claim 5 with the specific target and isolating a protein scaffold binding to the specific target with the predefined affinity. 
Postupak dobivanja proteinske platforme koja se veže za određenu metu sa prethodno definiranim afinitetom vezivanja, koji sadrži dovođenje u dodir biblioteke iz patentnog zahtjeva 5 sa specifičnom metom 1 izoliranje proteinske platforme koja se veže za određenu metu sa prethodno definiranim afinitetom.
(AP) The Compound of Paragraph (AO) where R4 is methyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što je R* jednako vodik, R* je metil, R!
reagent (Q3-reag) is selected from the group consisting of water, methanol, ethanol, oxalic acid, citric acid, NH4Cl, HCl, HBr, HNO3, H2SO4, H3PO4, acetic acid, propionic acid, formic acid and mixtures thereof. 
Reagens (Q3-reag.) je odabran iz skupine koja se sastoji iz vode, metanola, etanola, oksalne kiseline, limunske kiseline, NH,CI, HC1, HBr, HNO;, H2SOx4, H3POy, octene kiseline, propionske kiseline, mravlje kiseline i njihovih mješavina.
The method of claim 2, wherein the agent comprises a small molecule, a large molecule, a peptide, an antibody, a nucleic acid, or a biologically active fragment thereof. 
Primjena patentnog zahtjeva 6, gdje agens sadrži mali molekul, veliki molekul, peptid, antitelo, nukleinsku kiselinu, ili njihov biološki aktivan fragment.
The shank (22) of the pressure controller is provided with one end (26) wherein a threaded hole (23) is obtained, axially extending inside the shank (22). 
= Držač (22) ili pilot uređaj koji viri 12 prirubnice i ima kraj (26) opskrbljen otvorom s navojem (23),
In some embodiments, the solvent is selected from ethanol, isopropyl alcohol, aryl alcohol alcohols, ethers, ketones, esters, xylene, N-methylpyrrolidinone, and the mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine alkohols, eteri, ketoni, esteri, ksilen i N-metilpirolidinon, te smjese 2 ili više njih.
The compound according to claim 6, wherein is (C2-C6)alkenyl, aryl, halogen, aryl-S—, heteroaryl or aryl(C1-C6)alkyl, wherein said aryl or heteroaryl as such or as part of another group is unsubstituted or substituted with 1 or 2 substituent(s) R6; 
R' je (C,-Cs)alkenil, halogen, aril-S- ili ari KC,-Cs)alkil, pri čemu je rečeni aril kao dio druge skupine nesupstituiran ili supstituiran s 1 ili 2 supstituenta Rx, Rs je, neovisno pri svakom pojavljivanju, (Ci-Cg)alkil, halogen ili (Ci-Cs)alkoksi.
The FGF-18 compound for use according to claim 6, wherein the FGF-18 compound is to be administered at a dose of 1-100 mcg, preferably 5-40 mcg, preferably 10-30 mcg per single intra-articular administration. 
Spoj FGF-18 za uporabu prema zahtjevu 6,: naznačen time da se spoj FGF-18 daje u dozi od 1-100 mcg, poželjno 5-40 mcg, poželjno 10-30 meg po jednom intra-artikularnom davanju.
Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of respiratory diseases: in which: 
Uporaba spoja prikazanog formulom (I), ili njegovih farmaceutski prihvatljivih soli ili solvata u proizvodnji lijeka za liječenje respiratornih bolesti:
The method of any one of claims 1 to 3, wherein the end marker in the special data packet is set in a header of the special data packet to indicate that the special data packet is the last data packet sent from the source eNB to the target eNB. 
Postupak prema bilo kojem zahtjevu od 1 do 3, naznačen time da, kada target eNB prosljeđuje pakete korisničkih podataka isporučene od SGW prema UE nakon prijema posebnog paketa podataka od izvorišnog eNB, ciljni eNB ne prosljeđuje poseban paket podataka prema UE.
This heater can be mounted in the electrically heated smoking system using a special frame, for example a metallic clamp, or the heater may be an integral part of a monolithic ceramic base sitting within the electrically heated smoking system. 
Električno grijani sustav za pušenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se, tijekom rada, supstrat koji stvara aerosol dijelom nalazi u električno grijanom sustavu za pušenje.
The pharmaceutical composition for use according to claim 2, wherein Ra2 is selected from hydrogen, C1-C6 alkyl substituted with heterocyclyl, unsubstituted C1-C6 alkoxy, amino, and heterocycle. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra, odabran od sljedećih: vodik, C,-Cg alkil supstituiran s heterociklom, nesupstituirani C,-Cg alkoksi, amino i heterocikl.
This disclosure herein is intended to be exemplary, and not limiting. The scope of the invention is defined by the claims appended hereto. A neck ring guide for aligning neck ring sections in a glassware forming machine, characterized in that said neck ring guide includes a hub (132) and a separate reusable guide plate (134) replaceably mounted on said hub, said guide plate having spaced parallel runners (136) for receipt of guide slots in the neck ring sections. 
Vodilica prstena grla u skladu s jednim od patentnih zahtjeva 1 do 8, naznačena time što navedeno središnje tijelo ima glavčinu (132) i odvojenu ploču za vođenje (134) koja se može ponovno koristiti i koja je montirana na navedenu glavčinu, i to na takav način da se može zamijeniti, pri čemu su navedeni razmaknuti klizni elementi (136), koji su namijenjeni da budu umetnuti u prorez za vođenje sekcije prstena grla, dio ploče za vođenje (134).
RF2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl; 
R'? je odabran iz skupine koja sadrži vodik, halogen, po izboru supstituiran C,. alkil, po izboru supstituiran C,. salkenil i po izboru supstituiran C>2.g alkinil;
At least a part of the inner part may be shaped so as to engage at least a part of the at least one element in the packaging. 
Najmanje jedan dio unutarnjeg dijela može biti oblikovan tako da zahvaća najmanje jedan dio najmanje jednog elementa u pakiranju.
wherein a loading dose treatment period precedes the weekly application and wherein the loading dose treatment period comprises daily application of the composition to the affected areas of said patient for one month. 
Pripravak za primjenu prema patentnom zahtjevu 3, naznačen time, što se razdoblje liječenja inicijalnom dozom sastoji od dnevnog nanošenja tijekom mjesec dana.
The liquefied gas treatment system according to claim 7, wherein the boil-off gas supplied to the heat exchanger is a boil-off gas compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7 ili 8, naznačen time što je otpareni plin poslan u izmjenjivač topline (21) otpareni plin, koji se komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
a method for producing a compound represented by the following formula (A), comprising the steps of: 
Postupak proizvodnje spoja predstavljenog sljedećom formulom (A), koji obuhvaća korake:
The method according to claim 22, wherein the point mutation is a point mutation in the cysteine-rich domain or in the tyrosine kinase domain of RET tyrosine kinase. 
Postupak u skladu s patentnim zahtjevom 21, naznačen time što je točkasta mutacija točkasta mutacija u cisteinom bogatoj domeni ili u tirozinsko-kinaznoj domeni tirozinske kinaze RET.
To the mixture was added 3 mL 1 M borane in tetrahydrofuran and the mixture was stirred at room temperature for 24 hours. 
Smjesi je dodano n 3 mL IM borana u tetrahidrofuranu i smjesa je miješana na sobnoj temperaturi 24 sata.
. A process according to any one of claims 1 to 4 or use according to claim 5, wherein said (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H -3-benzazepine hydrochloride hemihydrate gains less than about 1.0 % weight after undergoing a dynamic vapor sorption cycle from 10% RH to 90% RH. 
Hemihidrat u skladu sa zahtjevom 1, naznačen time, da navedeni spoj dobiva manje od oko 1.0% mase nakon podvrgavanja ciklusu dinamičke sorpcije para od 10% RH do 90% RH.
FIG. 1 shows a perspective view of an assembled inhaler, which includes a strap according to a preferred form of the present invention, the strap being shown in a closed condition; 
Slika 1 je pogled u perspektivi na sklopljeni inhalator, koji sadrži vrpcu sukladno poželjnom obliku ovog izuma, a vrpca je prikazana u zatvorenom položaju.
A bus according to claim 8, characterised in that the pressure means comprise a compressor. 
Autobus u skladu s patentnim zahtjevom 8, naznačen time što tlačni element sadrži kompresor.
stereo isomers such as the respective enantiomers, in particular the respective R-or S-enantiomers (including salts, ester, amides), c) respective esters, e.g. 
stereoizomere, kao što su odgovarajući enantiomeri, posebno odgovarajući R- ili S-enantiomeri (uključujući soli, estere, amide), c) odgovarajuće estere, npr.
The method of claim 20, wherein the discharging of air into the shoe includes discharging the air intermittently. 
Postupak prema zahtjevu 13, naznačen time da ispuštanje zraka u papučicu (126) obuhvaća njegovo naizmjenično ispuštanje.
FRa levels derived from subjects identified as having early-stage folate receptor alpha-expressing cancer; 
razine FRa dobivene kod subjekata za koje je identificirano da imaju kasni stadij raka koji eksprimira folatni receptor a.
Example 7 Compounds of Formula I 
Primjer 7 - Spojevi formule I Sinteza 128.
The applicants have surprisingly found that quinazoline derivatives having substituents (for example halogeno substituents) at 2- and 3- positions or at 2-, 3- and 4-positions on the benzene ring compared to quinazoline derivatives having substituents at 3-and 4- positions on the benzene ring produces compounds with enhanced activity in that the compounds have an increased potency againsterbB2 and/or EGFR (particularly erbB2) receptor tyrosine kinases in cellular assays. 
Prijavitelji su začudo pronašli da su derivati kinazolina koji imaju supstituente (na primjer halogene supstituente) na položajima 2- i 3-, ili položajima 2-, 3- i 4- benzenskog prstena, u usporedbi sa derivatima kinazolina koji imaju supstituente na položajima 3- i 4- benzenskog prstena, spojevi sa pojačanim djelovanjem, to jest, da takvi spojevi u staničnim testovima pokazuju povećanu aktivnost prema erbB2 i/ili EGFR (a posebice erbB2) receptorskim tirozin kinazama.
In one embodiment the present invention provides a cell comprising a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene and no further mutated protease genes. 
omutirani Tsp gen, pri čemu mutirani Tsp gen kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze od divljeg tipa ne-mutiranog Tsp ili je,knockout" mutirani Tsp gen; i b.
A compound which is 2-(3,5-Dichloro-1-oxido-pyridine-4-yl)-1-(7-difluoromethoxy-2',3',5',6'-tetrahydro-spiro[1,3-benzodioxole-2,4'-(4H)-pyran]-4-yl)ethanone, or a pharmaceutically acceptable hydrate or solvate thereof, for use in the treatment of proliferative and inflammatory skin disorders such as psoriasis, epidermal inflammation, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis and eczema. 
Spoj koji je 2-(3,5-Dikloro-1-oksido-piridin-4-il)-1-(7-difluorometoksi-2*,3*,5',6'-tetrahidro-spiro[1,3-benzodioksol-2,4' (4H)-piran]-4-ilhetanon, ili parmaceutski prihvatljiv hidrat ili solvat istih, za uporabu u liječenju proliferativnih i upalnih kožnih poremećaja poput psorijaze, epidermalne upale, akni, dermatitisa, atopijskog dermatitisa, seboreičnog dermatitisa, kontaktnog dermatitisa, urtikarije, pruritisa i ekcema.
and finally with addition of morpholine to give the compound of the formula (IIIa). 
Postupak prema zahtjevu 2, naznačen time što je . aldehid u ciklizacijskoj rike spoj s formulom (IIIa)
A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 7 and at least one pharmaceutically acceptable excipient. 
Farmaceutska kompozicija koja sadrži spoj sa formulom (1) i vodeni pufer, gdje kompozicija ima pH od oko 5 do oko 6.
mounting an opposite end of said at least one insulator onto the free end of the manipulatable boom. 
montiranje suprotnog kraja od navedenog najmanje jednog izolatora na slobodni kraj adapterske poluge (40) kojom se može upravljati.
The virion or virus particle according to claim 1 or claim 2, wherein the photoreceptor-specific human rhodopsin kinase promoter comprises a nucleic acid sequence that consists essentially of an at least 60 contiguous basepair sequence from SEQ ID NO:12. 
TAAV vektor prema zahtjevu 1 ili zahtjevu 2, naznačen time što promotor fotoreceptorski specifične ljudske rodopsin kinaze sadrži sekvencu nukleinske kiseline koja se uglavnom sastoji od najmanje 60 susjednih sekvenci osnovnog para iz SEQ ID NO: 12.
lenalidomide (25 mg) orally administered for 21 days (Days 15-35; Cycle 1) and Days 1-21 (Cycle 2 and subsequent cycles); and 
(b) _lenalidomid (25 mg po) administriran tijekom 21 dana (Dani 15-35; Ciklus 1) i na Dane 1-21 (Ciklus 2 i slijedeći ciklusi); i
The benzyl-protected intermediates (II) can be prepared by the Hantzsch synthesis, as follows:- 
(a) Benzil-zaštićeni intermedijeri (II) mogu se dobiti Hantsch-ovom sintezom na slijedeći način:
The organic phase was separated and filtered through a Whatman 5 uM filter tube, washing the filter cake with methanol (2×1 mL). 
Organsku fazu se odvoji, te pročisti kroz 5 uM cijevni Whatmanov filtar, uz ispiranje filtarskog kolača metanolom (2 X 1 ml).
A transgenic plant cell obtained according to the method of any of aspects 74 or 75. 
Transgenska biljna stanica ili transgenska biljka, naznačena time, da se dobiva u skladu s postupkom prema zahtjevu 10ili 11.
in a first phase, injecting the injection material only through those injection lines which extend transversely, 
u prvoj fazi, injiciranje injekcijskog materijala samo kroz te injekcijske linije (12) koje se pružaju transverzalno,
A vector comprising the nucleic acid molecule of claim 1. 
Vektor, koji obuhvaća molekulu nukleinske kiseline prema zahtjevu 1.
The compound of Claim 1 wherein R3 is methyl. 
Spoj prema patentnom zahtjevu 1, naznačen time što je R* jednako metil.
A compound of formula (I) according to claim 1 wherein R2 is C1-3alkyl substituted by aryl, heterocycle, or heteroaryl which is further substituted by C1-3alkyl, alkoxy, carboxylic ester or carboxylic amide and wherein R1 and R3 are as specified above. 
Spoj s formulom (I) prema patentnom zahtjevu 1 naznačen time što R2 je C1-3alkil supstituiran s arilom, heterociklom, ili heteroarilom koji je nadalje supstituiran s C1-3alkilom, C1-6alkoksi, karboksilnim esterom ili karboksilnim amidom i pri čemu R1 i R3 su kako je gore navedeno.